Urotensin II Signaling in Cardiovascular Health and Disease

Urotensin II (UII) is a cyclic peptide hormone recognised as one of the most potent vasoactive agents in the human cardiovascular system. Synthesised primarily in the heart, vasculature and adrenal glands, UII exerts its effects through binding to the G protein-coupled UT receptor, triggering downstream cascades such as phospholipase C activation, protein kinase C and mitogen-activated protein kinase pathways. In healthy vessels, UII contributes to the fine-tuning of vascular tone by promoting endothelium-dependent vasodilatation via nitric oxide and endothelium-independent vasoconstriction. In pathological states, upregulation of UII and UT has been linked to hypertension, heart failure, myocardial ischaemia, atherosclerosis and vascular remodelling. Mechanistic studies reveal that UII can drive reactive oxygen species generation, RhoA/ROCK-mediated cytoskeletal changes, cardiomyocyte hypertrophy and inflammatory cell recruitment. Emerging evidence also highlights cross-talk with gasotransmitters such as hydrogen sulphide. Therapeutic modulation of the UII–UT axis using selective antagonists or biased ligands offers promise in attenuating maladaptive remodelling, protecting against ischaemia–reperfusion injury and ameliorating blood pressure control. Continued exploration of receptor localisation, ligand bias and interconnections with metabolic and inflammatory networks will be essential to unlock clinical potential.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Urotensin II Signaling in Cardiovascular Health and Disease publication trend

The graph below shows the total number of articles in urotensin ii signaling in cardiovascular health and disease across all publications each year (not limited to Nature Index journals).

Technical terms

Urotensin II (UII): A cyclic peptide hormone that modulates vascular tone and cardiac function.

Urotensin II receptor (UT): A G protein-coupled receptor mediating UII signalling in vascular and cardiac tissues.

G protein-coupled receptor (GPCR): A membrane receptor family that transduces extracellular signals via G-protein activation.

RhoA/ROCK pathway: A signalling cascade regulating cytoskeletal organisation and vascular smooth muscle contraction.

Ischaemia–reperfusion injury: Tissue damage caused by restoration of blood flow following a period of restricted perfusion.

Oxidative stress: An imbalance between reactive oxygen species production and antioxidant defences.

Cystathionine-γ-lyase (CSE): An enzyme responsible for generating hydrogen sulphide, a cardioprotective gasotransmitter.

References

1. Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway. PLOS ONE (2016).
2. Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway. International Journal of Molecular Sciences (2015).
3. Association between Human Urotensin II and Essential Hypertension—A 1:1 Matched Case-Control Study. PLOS ONE (2013).
4. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. Frontiers in Endocrinology (2013).
5. Potential Clinical Implications of the Urotensin II Receptor Antagonists. Frontiers in Pharmacology (2011).